This counter up or down easily due to about 15% of the share in the market. I will accumulate when the price is drop. With Pharma ventures into Indonesia and Arab will see the result started by coming year.
As Dow and Nasdaq down again that may put the world ecomonic to some degree of uncertainty, will further accumulate Pharma at rm4.2x as business will still as usual for Pharma. This long term investment will provide me some return better than fd.
Here are the top picks|tp from hleb workshop: brahim |rm3.13 ioi prop |rm3.85 mahb |rm10.55 maybank |rm11.98 pharma |rm5.30 tenaga |rm13.50 rhb cap |rm9.59 sk petro |rm5.52 perdana |rm2.18 qct |rm1.28
Present growth is driven by lical performance, only start next year will see Indonesia contribution and next 3~5 years from Arab. i expect Pharma price is able to reach tp of rm5.00 this year and next year is rm5.50 plus at least 4~6% dividend.
Hiewan, you are better than me. So far, my investment (for long term) in this counter is about 30K+. It is good opportunity to accumulate below or at RM4.30 since not many people aware the potential of this counter.
CIMB starts coverage this counter n given target price at RM6.50,all the while this counter had been under price,so it is good sign CIMB start coverage n wish the price can move to higher level.
this is a good counter,they supply 50% of the medicines to MOH,if not mistaken,every q they issue dividend,wish EPF fund manager can study this counter n buy in.Beside CIMB,HLG also given higher target price than the current market price,that is RM5.30.
Edited CIMB Research We begin coverage of the stock with an Add rating and target price of RM6.50, based on 19.2x CY15 P/E, a 20% premium over its 3-year average forward P/E in view of its strong EPS CAGR of 28.1% for FY13-16. We like its strong market positioning and manufacturing growth potential. Stronger earnings and higher dividends are potential catalysts, in our view.
Under-researched stock with strong earnings growth Pharmaniaga is an under-researched stock, in our view, as it is covered by only one broker currently, according to Bloomberg. However, we think that Pharmaniaga warrants a closer look by investors. The group is the largest pharmaceutical stock in Malaysia by market cap. It is well positioned to tap the rising healthcare spending in Malaysia via its Concession Agreement with MOH. The group’s manufacturing division could also benefit from the patent cliff, which allows it to launch more products in the next few years. We expect the manufacturing division to be the main thrust of earnings growth as in-house products have much higher profit margins vis-à-vis distributing third-party products.
i don't think there is any latest news as they ventured in indonesia and setup a plant in Arab are already too busy for them (is i am not wrong, appeared in newspaper 2~3 wks ago)
i alert my fren since 4.18(date : 9th April 2014 )and say im going to buy .. but at the same time i bought karex make some profit then run, so this didnt buy this counter ... damn ....
but how come so quite coz no company announcement .......
if tmr this counter is fine then maybe 1st TP 4.90 2nd TP 5.00
yes....that was CIMB TP which is possible...heard from the grapevine that some positive news will be out soon on the APPL results....then it will shoot....better don't lose this good opportunity now...
Earlier morning bought at RM4.60, It is a suprise to me as i always feel confident of this counter even is not bought them in low price..may be it is a good deeds to invest in company that can serve people.
Malaysia does not have any high profile pharmaceutical company such as Pfizer, Merck, Ely Lily, Astra Zeneca and many other top companies. There are only generic companies and the top notch which acquired government hospital procurement is Pharmaniaga. As long as the tender with government hospital never end, this company will constantly growing .. be it slow . it still grows .. Pharmaceutical sector is one that will keep on growing as long as people are becoming older with longer life span.
This counter is for long term investment especially we can see the contribution from Indonesia is at least end of next year and the jv plant in Saudi is 2~2 years time.
New IPO: The largest mini-market player and a leading groceries retailer in Malaysia, 99 Speed Mart Retail Holdings Bhd aims to list on the Main Market!
MQ Trader 894 views | 4 d ago
0:17
New IPO: An enterprise IT solutions provider that provides implementation services, maintenance, support and professional services, Vetece Holdings Bhd aims to list on the Ace Market!
MQ Trader 761 views | 8 d ago
0:17
New IPO: A manufacturing and trading of biomass fuel products, particularly PKS and wood pellets company, Elridge Energy Holdings Bhd aims to list on the Ace Market!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Investeye
2,347 posts
Posted by Investeye > 2014-04-10 09:19 | Report Abuse
This counter up or down easily due to about 15% of the share in the market. I will accumulate when the price is drop. With Pharma ventures into Indonesia and Arab will see the result started by coming year.